Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-17T17:04:59.038Z Has data issue: false hasContentIssue false
  • English
  • Français

Why is the Pharmaceutical Industry Investing Increasing Amounts in Health Economic Evaluations?

Published online by Cambridge University Press:  10 March 2009

Fredrik Andersson
Fredrik Andersson
Affiliation:
Astra Hässle AB
Get access Rights & Permissions [Opens in a new window]

Abstract

Over the last few years, the pharmaceutical industry has financed an increasing number of health economic evaluations. The purpose of this article is to describe how and why the pharmaceutical industry is applying health economic evaluations. Seven different fields of application are identified, and the varying reasons for use are discussed.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 11 , Issue 4 , Fall 1995 , pp. 750 - 761
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Adams, M. E., McCall, N. T., Gray, D. T., et al. Economic analysis in randomized control trials. Medical Care, 1992, 30, 231–43.CrossRefGoogle ScholarPubMed
2.Andersson, F., & Hatziandreu, E.The costs and benefits of switching a drug from prescription-only to over-the-counter status: A review of methodological issues and current evidence. PharmacoEconomics, 1992, 2, 388–96.CrossRefGoogle ScholarPubMed
3.Andersson, F., & Hertzman, P.Effective patent life of drugs in Sweden: A comparison with international studies. Managerial and Decision Economics, 1993, 14, 53–63.CrossRefGoogle Scholar
4.Aristides, M., & Mitchell, A.Applying the Australian guidelines for the reimbursement of Pharmaceuticals. PharmacoEconomics, 1994, 6, 196–201.CrossRefGoogle ScholarPubMed
5.Buxton, M. J., & O'Brien, B. J.Economic evaluation of Ondansetron: Preliminary analysis using clinical trial data prior to price-setting. British Journal of Cancer, 1992, 66(Suppl 19), 64–67.Google Scholar
6.Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of Pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.Google Scholar
7.Clemens, K., Garrison, L. P. Jr., Jones, A., & Macdonald, F.Strategic Use of pharmaco-economic research in early drug development and global pricing. PharmacoEconomics 1993, 4, 315–22.CrossRefGoogle Scholar
8.Commonwealth of Australia. Guidelinesfor the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analysis. Canberra: Department of Health, Housing and Community Services, 1992.Google Scholar
9.Culyer, J. A., & Horisberger, B. (eds.), Economic and medical evaluation of health care technologies. Berlin: Springer-Verlag, 1983.CrossRefGoogle Scholar
10.Detsky, A.Guidelines for economic analysis of pharmaceutical products: A draft document for Ontario and Canada. PharmacoEconomics, 1993, 3, 354-61.CrossRefGoogle ScholarPubMed
11.DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L.Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 1991, 10, 107–42.CrossRefGoogle ScholarPubMed
12.Drummond, M.Australian guidelines for cost-effectiveness studies of Pharmaceuticals: The thin end of the boomerang? PharmacoEconomics, 1992, 1(Suppl 1), 61–69.CrossRefGoogle ScholarPubMed
13.Drummond, M., Brandt, A., Luce, B., & Rovira, J.Standardizing methodologies for economic evaluation in health care: Practice, problems, and potential. International Journal of Technology Assessment in Health Care, 1993, 9, 26–36.CrossRefGoogle ScholarPubMed
14.Drummond, M., Rutten, F., Brenna, A., et al. Economic evaluation of Pharmaceuticals: A European perspective. PharmacoEconomics, 1993, 4, 173–86.Google ScholarPubMed
15.Europe's new cost-conscious environment. IMS Marketletter, 1993, 20 (8 11), 24–25.Google Scholar
16.FDA being “drawn into” cost-effectiveness field through ad oversight, Kessler says: Agency is receiving cost studies with NDAs, ‘increasing role’ predicted. F-D-C Reports, 1993, 55 (1 11), 8–9.Google Scholar
17.FDA on cost-effectiveness claims. IMS Marketletter, 1993, 20 (22 11), 15.Google Scholar
18.Freemantle, N., & Maynard, A.Something rotten in the state of clinical and economic evaluations? Health Economics, 1994, 3, 63–67.CrossRefGoogle ScholarPubMed
19.Gafni, A., & Birch, S.Guidelines of the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. Canadian Medical Association Journal, 1993, 148, 913–17.Google ScholarPubMed
20.Gerdtham, U-G., & Jönsson, B.Läkemedelsförmànen (In Swedish: The Pharmaceutical Subsidy). Stockholm: SNS Förlag, 1993.Google Scholar
21.Hendry, D.Economic analysis as an aid to subsidisation decisions: The development of Australian guidelines for Pharmaceuticals. PharmacoEconomics, 1992, 1, 54–67.Google Scholar
22.Hertzman, P.Hälsoekonomiska investeringskalkyler i Sverige 1975–1989 (In Swedish Health economic analyses in Sweden 1975–1989). Working Paper Series 1/92. Lund: Department of Economics, Lund University, Sweden, 1992.Google Scholar
23.Hillman, A. L., Eisenberg, J. M., Pauly, M. V., et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. The New England Journal of Medicine, 1991, 324, 1362–65.CrossRefGoogle ScholarPubMed
24.Johannesson, M.The Australian guidelines for subsidisation of Pharmaceuticals: The road to cost-effective drug-prescribing? PharmacoEconomics, 1992, 2, 355-62.CrossRefGoogle ScholarPubMed
25.Kassirer, J. P., & Angell, M.The journal's policy on cost-effectiveness analyses. The New England Journal of Medicine, 1994, 331, 669–70.CrossRefGoogle ScholarPubMed
26.Kemp, R., & Wlodarczyk, J.Australian pharmaceutical pricing guidelines: Preliminary practical experience. PharmacoEconomics, 1994, 5, 465–71.Google ScholarPubMed
27.Laupacis, A., Feeny, D., Detsky, A. S., & Tugwell, P. X.How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992, 146, 473–81.Google ScholarPubMed
28.Laupacis, A., Feeny, D., Detsky, A. S., & Tugwell, P. X.Tentative guidelines for using clinical and economic evaluations revisited. Canadian Medical Association Journal, 1993, 148, 927–29.Google ScholarPubMed
29.Luce, B. R.Cost-effectiveness analysis: Obstacles to standardisation and its use in regulating Pharmaceuticals. PharmacoEconomics, 1993, 3, 1–9.CrossRefGoogle ScholarPubMed
30.MacDonald, F. Strategic use for pharmacoeconomics in the early stages of drug development. Presentation at Drug Information Association Workshop on Health Economics: The Impact of Economic Evaluation on New Drug Development and Marketing. Lisbon, 11 14–17, 1993.Google Scholar
31.New UK guidance on economic evaluation. SCRIP, 1994, 1926, 3.Google Scholar
32.Ontario Ministry of Health. Guidelinesfor preparation of economic analysis to be include in submission to drug programs branch for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index. Toronto: Drug Programs Branch, Ministry of Health, 1991.Google Scholar
33.Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Drug Programs Branch, Ministry of Health, 1994.Google Scholar
34.Organization for Economic Cooperation and Development. OECD health data: Comparative analysis of health systems. CREDES-OECD Database. Paris: OECD, 1991.Google Scholar
35.Risks of early cost-benefit conclusions. SCRIP, 1993, No. 1876, 27.Google Scholar
36.SBU. Mattligt förhöjt blodtryck (In Swedish: Mild to moderately raised blood pressure). Stockholm: Statens beredning för utvärdering av medicinsk metodik (SBU —Swedish Council on Technology Assessment in Health Care), 121, 1994.Google Scholar
37.Strandberg, K., Kommentar, (In Swedish: Comment). In Johannesson, M. & Jonsson, B. (eds.), Ekonomisk utvärdering av Iäkemedel (In Swedish: Economic assessment of pharmaceuticals). Stockholm: SNS Förlag, 1993, 111–13.Google Scholar
38.Udvarhelyi, I. S., Colditz, G. A., Rai, A., & Epstein, A. M.Cost-effectiveness and cost-benefit analyses in the medical literature: Are the methods being used correctly? Annals of Internal Medicine, 1992, 116, 238–44.CrossRefGoogle ScholarPubMed
39.Walker, S. Socioeconomic evaluation of medicines: A survey of the global pharmaceutical industry. Presentation at the Drug Information Association Workshop on Health Economics: The Impact of Economic Evaluation on New Drug Development and Marketing. Lisbon, 11 14–17, 1993.Google Scholar
40.Wells, N. E. J.Regulation of the pharmaceutical industry: And now pharmacoeconomic research? PharmacoEconomics, 1992, 2, 435–39.CrossRefGoogle ScholarPubMed